
HER2-Positive Gastrointestinal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Implications of zanidatamab front-line data
Experts debate whether zanidatamab should supplant trastuzumab backbones and foresee continued immunotherapy incorporation.
Play episode from 19:32
Transcript


